Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02055092
Other study ID # 229002
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 2014
Est. completion date July 2020

Study information

Verified date March 2021
Source Norwegian Centre for Ageing and Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

People diagnosed with young onset dementia are today mostly assigned to the same healthcare services as people developing dementia at an older age. They and their families are however in a quite different life situation, which is likely to generate different challenges and specific needs for tailored healthcare services, of importance in maintaining their perceived quality of life. The investigators of this study wish to assess the factors influencing these families' quality of life, their specific needs and their use of healthcare services by the use a combination of quantitative and qualitative methods. The main aim of this study is to provide better future healthcare services to these families, and to develop a programme for optimal collaboration between specialist healthcare services and the local dementia teams.


Description:

Background: Most common dementia cases in Young Onset dementia (YOD) are Alzheimer's disease (AD) and frontotemporal dementia (FTD). There is little knowledge about the impact on the affected families, especially with regard to FTD. Although their life situation and specific needs differ from that of older people, they are referred to the same healthcare services. Hypothesis: 1. QoL is poorer among persons with FTD and their families compared to AD at baseline. 2. There is less worsening of QoL after two years in persons with AD and their families compared to FTD. 3. People with YOD have different needs for health care services than older people with dementia. 4. YOD and their families have more unmet needs than older people with dementia. Methods: Nordic multicenter observational cohort study of YOD-AD and YOD-FTD. 75 persons in each group, living at home with their families, recruited from five Norwegian and four Nordic memory clinics. The control group consists of 100 older people with dementia age ≥70 years. The investigators use a combination of quantitative and qualitative methods. The follow-up period of the persons with YOD and their family members is two years. Assessments are made at baseline, 12 and 24 months, with telephone check-ups at 6 and 18 months. The main assessment questionnaires are Quality of life in Alzheimer's disease (QoL-AD), Camberwell Assessment of Need in the Elderly (CANE), and Resource Utilization in Dementia Lite (RUD Lite). Study aims for the quantitative part of the study: 1. To evaluate the quality of life of persons with YOD and their family members. 2. To identify and explore the specific needs of YOD and their families. 3. To assess the use of health resources and calculate the costs associated with care for YOD, in comparison with older persons with dementia. 4. To compare the functional characteristics of YOD with older people with dementia in terms of cognitive decline, impairment of activities of daily living, changes in behavior, and quality of life. Study aims and methods for the qualitative part of the study: 1. To investigate how people living alone with young-onset dementia cope with everyday life and decision-making. A longitudinal study with qualitative interviews at 6, 12, 24, 36 and 48 months after initial diagnosis 2. To investigate how it is to be a spouse/cohabitation to a person with young-onset of frontotemporal dementia. A retrospective and prospective study with qualitative interviews. 3. To investigate adult children's experiences with the support they received after their parent with young-onset dementia received a dementia diagnose. A retrospective and prospective study with qualitative interviews. 4. To investigate carers of people with young-onset dementia experiences with the support contact service. A longitudinell study study with qualitative interviews. Results: Inclusion starts Feb 2014. The objective of this study is to ensure optimally tailored service provision and future healthcare planning according to the specific needs of families of YOD, and develop a care programme in collaboration between primary and specialist healthcare services.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date July 2020
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group N/A to 69 Years
Eligibility Inclusion Criteria: - Debut of dementia symptoms before the age of 65 years, but age at time of inclusion may be up to 70 years. - FTD (Neary et al 1998 criteria) - Primary progressive aphasia (Mesulam 2003 criteria) - AD (DSM-IV) - Community living, excl. dementia-specific living facilities manned 24/7 - Family member with regular contact at least x 1/week. Exclusion Criteria: - Lack of informed consent - No close or appropriate family member - Frontal lobe dysfunction due to non-progressive injury, i.e. cerebral infarction - Frontal lobe dysfunction due to motor neuron disease (ALS) - Other dementia specific condition with frontal lobe dysfunction (Huntington, HIV, Down syndrome, alcoholic dementia) - Mental retardation - Current substance abuse, incl. excessive alcohol consumption for the past 12 months

Study Design


Locations

Country Name City State
Norway Norwegian Centre for Ageing and Health Tønsberg Vestfold

Sponsors (11)

Lead Sponsor Collaborator
Norwegian Centre for Ageing and Health Copenhagen University Hospital, Denmark, Haraldsplass Deaconess Hospital, Karolinska University Hospital, Landspitali University Hospital, Oslo University Hospital, Sykehuset Innlandet HF, Sykehuset Telemark, The Hospital of Vestfold, The Research Council of Norway, Zealand University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Other Clinical dementia rating Assessments by Clinical dementia rating scale (CDR) . Baseline
Other Awareness Assessments by REED scale. Baseline
Other Depressive symptoms Assessments by Cornell Scale for Depression in Dementia (CSDD) by proxy, and using Geriatric Depression Scale (GDS) and Montgomery-Asberg Depression Rating Scale (MADRS) in family member. Baseline
Other Coping Assessments by Locus, 17 item, for index person and family member. Baseline
Other Intercurrent disease Assessments by telephone follow-up interview with index person and family member. 6 months
Other Medication Baseline
Other Hospital admission Assessments by telephone follow-up interview with index person and family member. 6 months
Other Changes in living conditions Assessments by telephone follow-up interview with index person and family member. 6 months
Other Major life events Assessments by telephone follow-up interview with index person and family member. 6 months
Other Apo E4-genotype Whole blood collected at baseline, analysis may be performed at a later stage (stored in research bio bank). Baseline
Other Clinical dementia rating Assessments by Clinical dementia rating scale (CDR) . 12 months
Other Clinical dementia rating Assessments by Clinical dementia rating scale (CDR) . 24 months
Other Awareness Assessments by REED scale. 12 months
Other Awareness Assessments by REED scale. 24 months
Other Depressive symptoms Assessments by Cornell Scale for Depression in Dementia (CSDD) by proxy, and using Geriatric Depression Scale (GDS) and Montgomery-Asberg Depression Rating Scale (MADRS) in family member. 12 months
Other Depressive symptoms Assessments by Cornell Scale for Depression in Dementia (CSDD) by proxy, and using Geriatric Depression Scale (GDS) and Montgomery-Asberg Depression Rating Scale (MADRS) in family member. 24 months
Other Coping Assessments by Locus, 17 item, for index person and family member. 12 months
Other Coping Assessments by Locus, 17 item, for index person and family member. 24 months
Other Intercurrent disease Assessments by telephone follow-up interview with index person and family member. 18 months
Other Medication 12 months
Other Medication 24 months
Other Medication 6 months
Other Medication 18 months
Other Hospital admission Assessments by telephone follow-up interview with index person and family member. 18 months
Other Changes in living conditions Assessments by telephone follow-up interview with index person and family member. 18 months
Other Major life events Assessments by telephone follow-up interview with index person and family member. 18 months
Primary Quality of life Assessments by Quality of Life - Alzheimer's dementia (QoL-AD) and Euroqol-5D (EQ-5D), index person and family member; also by proxy (QoL-AD). Baseline
Primary Change from baseline in quality of life at 12 months Assessments by Quality of Life - Alzheimer's dementia (QoL-AD) and Euroqol-5D (EQ-5D), index person and family member; also by proxy (QoL-AD). Baseline, 12 months
Primary Change from baseline in quality of life at 24 months Assessments by Quality of Life - Alzheimer's dementia (QoL-AD) and Euroqol-5D (EQ-5D), index person and family member; also by proxy (QoL-AD). Baseline, 24 months
Secondary Specific needs Assessments by Camberwell Assessment of Need in the Elderly (CANE); 24 items for index person and 2 items for family member needs. Baseline
Secondary Use of healthcare resources Assessments by Resource utilization in dementia Lite (RUD Lite). Baseline
Secondary Cognition Assessments standardized by the National Registry of Dementia: Mini Mental Status-Norwegian revision (MMSE-NR), Clock drawing Test, Trail making test part A and B, 10-word list memory recall and recognition test, The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) visuospatial figure copying, FAS, Boston Naming Test, Informant questionnaire-on Cognitive decline in Dementia (IQ-CODE). Baseline
Secondary Neuropsychiatric symptoms Assessments by Neuropsychiatric Inventory- Questionnaire (NPI-Q). Baseline
Secondary Activities of Daily Living (ADL) Assessments by Lawton & Brody I-ADL and Physical Self-maintenance Scale (PSMS). Baseline
Secondary Relative's stress Assessments by Relative's Stress Scale (RSS). Baseline
Secondary Specific needs Assessments by Camberwell Assessment of Need in the Elderly (CANE); 24 items for index person and 2 items for family member needs. 12 months
Secondary Specific needs Assessments by Camberwell Assessment of Need in the Elderly (CANE); 24 items for index person and 2 items for family member needs. 24 months
Secondary Use of healthcare resources Assessments by Resource utilization in dementia Lite (RUD Lite). 12 months
Secondary Use of healthcare resources Assessments by Resource utilization in dementia Lite (RUD Lite). 24 months
Secondary Cognition Assessments standardized by the National Registry of Dementia: Mini Mental Status-Norwegian revision (MMSE-NR), Clock drawing Test, Trail making test part A and B, 10-word list memory recall and recognition test, The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) visuospatial figure copying, FAS, Boston Naming Test, Informant questionnaire-on Cognitive decline in Dementia (IQ-CODE). 12 months
Secondary Cognition Assessments standardized by the National Registry of Dementia: Mini Mental Status-Norwegian revision (MMSE-NR), Clock drawing Test, Trail making test part A and B, 10-word list memory recall and recognition test, The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) visuospatial figure copying, FAS, Boston Naming Test, Informant questionnaire-on Cognitive decline in Dementia (IQ-CODE). 24 months
Secondary Neuropsychiatric symptoms Assessments by Neuropsychiatric Inventory- Questionnaire (NPI-Q). 12 months
Secondary Neuropsychiatric symptoms Assessments by Neuropsychiatric Inventory- Questionnaire (NPI-Q). 24 months
Secondary Activities of Daily Living (ADL) Assessments by Lawton & Brody I-ADL and Physical Self-maintenance Scale (PSMS). 12 months
Secondary Relative's stress Assessments by Relative's Stress Scale (RSS). 12 months
Secondary Activities of Daily Living (ADL) Assessments by Lawton & Brody I-ADL and Physical Self-maintenance Scale (PSMS). 24 months
Secondary Relative's stress Assessments by Relative's Stress Scale (RSS). 24 months
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A